A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE

Masatoshi Kudo, Kazuomi Ueshima, Stephen L. Chan, Tomoko Aoki, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Mamoru Takenaka, Tomohiro Watanabe, Masahiro Morita, Chikara Ogawa, Yoshiyuki Wada, Masafumi Ikeda, Hiroshi Ishii, Namiki Izumi, Atsushi Hiraoka, Hiroshi Aikata, Naoshi Nishida

Article2022

LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC)

Anthony B. El-Khoueiry, Josep M. Llovet, Arndt Vogel, David C. Madoff, Richard S. Finn, Sadahisa Ogasawara, Zhenggang Ren, Kalgi Mody, Jerry J Li, Abby B. Siegel, Leonid Dubrovsky, Masatoshi Kudo

Journal of Clinical Oncology

Editorial Material2020

A new era of systemic therapy for intermediate and advanced stage hepatocellular carcinoma

Masatoshi Kudo

Article2024

Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma

Masatoshi Kudo